Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549365 | 0.87 | MAPT (0.52) | CYP3A4CHRM5CHKAMAPTSMN1; SMN2 | |
| SCHEMBL18762840 | 0.81 | CHRNA7 (0.43) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL27272478 | 0.78 | CYP3A4 (0.43) | CYP3A4CYP2C19CHRM5CHKASLC6A2 | |
| Pyrimidine SCHEMBL27553324 | 0.76 | MEN1 (0.44) | SLC6A2SLC6A4SLC6A3MAPTKDM4E | |
| SCHEMBL9348326 | 0.74 | ROCK2 (0.43) | CYP3A4CYP2C19MAPTKDM4EALDH1A1 | |
| SCHEMBL28844111 | 0.74 | ROCK2 (0.46) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL735155 | 0.74 | MEN1 (0.55) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL774509 | 0.74 | MEN1 (0.55) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL366705 | 0.74 | MEN1 (0.55) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6679513 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193752-B2 | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2314594-B1 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8501805-B2 | Substituted alpha-L-bicyclic nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2376516-B1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2356129-B1 | SUBSTITUTED ALPHA-L-BICYCLIC NUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20130041144-A1 | 5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8268980-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2066684-B1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120010393-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8088746-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547684-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-2066684-A2 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | Isis Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1984381-A2 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | Isis Pharmaceuticals, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7399845-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC | 2007-12-13 | — | — | US | disclosed |
| WO-2007134181-A2 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | FOUNDATION MEDICINE, INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007090071-A2 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | CYP3A4 2798/4885CYP2C19 3548/4885CHRM5 3787/4885 |
| US-20130041144-A1 | 5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | CYP3A4 4468/4885CYP2C19 4874/4885CHRM5 3051/4885 |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | CYP3A4 2703/4885CYP2C19 3784/4885CHRM5 3419/4885 |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | CYP3A4 2900/4885CYP2C19 3933/4885CHRM5 4393/4885 |
| US-20120010393-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | CYP3A4 2703/4885CYP2C19 3784/4885CHRM5 3419/4885 |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | CYP3A4 2900/4885CYP2C19 3933/4885CHRM5 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.